Literature DB >> 8891630

6-hydroxydopamine induces the loss of the dopaminergic phenotype in substantia nigra neurons of the rat. A possible mechanism for restoration of the nigrostriatal circuit mediated by glial cell line-derived neurotrophic factor.

K E Bowenkamp1, D David, P L Lapchak, M A Henry, A C Granholm, B J Hoffer, T J Mahalik.   

Abstract

Intraparenchymal injections of the neurotoxin 6-hydroxydopamine (6-OHDA) into the medial forebrain bundle in rats destroys the dopaminergic neurons in the pars compacta of the substantia nigra. In other transmitter systems it has been found that axotomy or neurotoxin exposure produces an initial loss of neurotransmitter phenotype, with cell death occurring over a much slower time course. To determine whether this also occurs in dopamine neurons after 6-OHDA, two approaches were utilized. First, the effect of injections of 6-OHDA into the medial forebrain bundle on nigral dopaminergic neurons was studied using combined fluorogold and immunocytochemical labeling. Four weeks after the 6-OHDA injection, there was an 85% reduction in the number of tyrosine hydroxylase (TH)-immunoreactive cells on the lesioned side. In contrast, there was only a 50% reduction in the number of fluorogold-labeled cells on the lesioned side. Second, the time course of the rescue of dopaminergic neurons after 6-OHDA by glial cell line-derived neurotrophic factor (GDNF) was determined using TH immunocytochemistry. Greater numbers of dopamine neurons were rescued 9 weeks after GDNF, compared with counts made 5 weeks after GDNF. Taken together, these results suggest loss of dopaminergic phenotype is greater than cell loss following 6-OHDA injections, and that GDNF restores the phenotype of affected cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891630     DOI: 10.1007/bf00229549

Source DB:  PubMed          Journal:  Exp Brain Res        ISSN: 0014-4819            Impact factor:   1.972


  30 in total

1.  The fate of prelabeled Clarke's column neurons after axotomy.

Authors:  R L McBride; E R Feringa; B E Smith
Journal:  Exp Neurol       Date:  1988-11       Impact factor: 5.330

2.  Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system.

Authors:  T Hökfelt; U Ungerstedt
Journal:  Brain Res       Date:  1973-10-12       Impact factor: 3.252

3.  6-Hydroxy-dopamine induced degeneration of central monoamine neurons.

Authors:  U Ungerstedt
Journal:  Eur J Pharmacol       Date:  1968-12       Impact factor: 4.432

Review 4.  Chemical neurotoxins as denervation tools in neurobiology.

Authors:  G Jonsson
Journal:  Annu Rev Neurosci       Date:  1980       Impact factor: 12.449

5.  The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease.

Authors:  K L Leenders; E P Salmon; P Tyrrell; D Perani; D J Brooks; H Sager; T Jones; C D Marsden; R S Frackowiak
Journal:  Arch Neurol       Date:  1990-12

6.  Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection.

Authors:  L R Williams; S Varon; G M Peterson; K Wictorin; W Fischer; A Bjorklund; F H Gage
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

7.  Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats.

Authors:  J L Hudson; C G van Horne; I Strömberg; S Brock; J Clayton; J Masserano; B J Hoffer; G A Gerhardt
Journal:  Brain Res       Date:  1993-10-29       Impact factor: 3.252

8.  Expression of GAP43 mRNA in normally developing and transplanted neurons from the rat ventral mesencephalon.

Authors:  G H Clayton; T J Mahalik; T E Finger
Journal:  J Comp Neurol       Date:  1994-09-15       Impact factor: 3.215

9.  [3H]GBR 12935 binding to dopamine uptake sites: subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy.

Authors:  J M Maloteaux; M A Vanisberg; C Laterre; F Javoy-Agid; Y Agid; P M Laduron
Journal:  Eur J Pharmacol       Date:  1988-11-08       Impact factor: 4.432

10.  Localization of damage induced by reactive oxygen species in cultured cells.

Authors:  S M Vroegop; D E Decker; S E Buxser
Journal:  Free Radic Biol Med       Date:  1995-02       Impact factor: 7.376

View more
  19 in total

Review 1.  Neurorestoration.

Authors:  Mikko Airavaara; Merja H Voutilainen; Yun Wang; Barry Hoffer
Journal:  Parkinsonism Relat Disord       Date:  2012-01       Impact factor: 4.891

2.  Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit.

Authors:  N Rampersaud; A Harkavyi; G Giordano; R Lever; J Whitton; Ps Whitton
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

3.  An angiogenic inhibitor, cyclic RGDfV, attenuates MPTP-induced dopamine neuron toxicity.

Authors:  Aditiben Patel; Giuseppe V Toia; Kalea Colletta; Brinda Desai Bradaric; Paul M Carvey; Bill Hendey
Journal:  Exp Neurol       Date:  2011-06-15       Impact factor: 5.330

Review 4.  Treatment of Parkinson's disease : what's on the horizon?

Authors:  Stacy S Wu; Steven J Frucht
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

5.  Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats.

Authors:  Santosh Kumar Prajapati; Debapriya Garabadu; Sairam Krishnamurthy
Journal:  Neurotox Res       Date:  2017-01-27       Impact factor: 3.911

6.  Intrastriatal injection of an adenoviral vector expressing glial-cell-line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease.

Authors:  A Bilang-Bleuel; F Revah; P Colin; I Locquet; J J Robert; J Mallet; P Horellou
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

7.  IGF-1 protects dopamine neurons against oxidative stress: association with changes in phosphokinases.

Authors:  Amina El Ayadi; Michael J Zigmond; Amanda D Smith
Journal:  Exp Brain Res       Date:  2016-02-19       Impact factor: 1.972

8.  Prenatal LPS increases inflammation in the substantia nigra of Gdnf heterozygous mice.

Authors:  Ann-Charlotte Granholm; Vandana Zaman; Jennifer Godbee; Michael Smith; Riad Ramadan; Claudia Umphlet; Patrick Randall; Narayan R Bhat; Baerbel Rohrer; Lawrence D Middaugh; Heather A Boger
Journal:  Brain Pathol       Date:  2010-12-08       Impact factor: 6.508

9.  VGluT2 Expression in Dopamine Neurons Contributes to Postlesional Striatal Reinnervation.

Authors:  Willemieke M Kouwenhoven; Guillaume Fortin; Anna-Maija Penttinen; Clélia Florence; Benoît Delignat-Lavaud; Marie-Josée Bourque; Thorsten Trimbuch; Milagros Pereira Luppi; Alix Salvail-Lacoste; Pascale Legault; Jean-François Poulin; Christian Rosenmund; Raj Awatramani; Louis-Éric Trudeau
Journal:  J Neurosci       Date:  2020-09-14       Impact factor: 6.167

10.  Enriched environment protects the nigrostriatal dopaminergic system and induces astroglial reaction in the 6-OHDA rat model of Parkinson's disease.

Authors:  Agustín Anastasía; Luciana Torre; Gabriel A de Erausquin; Daniel H Mascó
Journal:  J Neurochem       Date:  2009-02-20       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.